https://jnj63533054agonist.com..../dread-during-the-pa
Bypassing representatives can help help restore haemostasis in inhibitor customers. Several novel representatives have already been developed, including the FVIII mimetic agent emicizumab, which was effective in reducing the annualized bleeding rate in haemophilia A patients with inhibitors. When coadministered with repeated large amounts of activated prothrombin complex concentrate (ie 100 U/kg/d for ≥24 hours), emicizumab had been associated with thrombotic microangiopathy and thrombo
Like
Comment
Share
